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Abstract
Background: Acute liver failure (ALF) is a complicated clinical syndrome associated with high mortality, with liver
transplantation as the only treatment option. Treatment of mesenchymal stem cells has shown a potential
therapeutic option for acute liver failure. However, the lack of random clinical trials and large non-human primate
studies makes it necessary to assess the efficacy and safety in the clinic.
Methods: We treated the monkeys with peripheral delivery of human umbilical MSCs (hUC-MSCs) and investigated
the role of hUC-MSCs in modulating the progress of acute liver failure.
Results: The use of early peripheral infusion of human umbilical cord MSC infusion did not improve liver
regeneration or modulate adaptive immunity. However, it significantly suppressed the hepatic aggregation and
maturation of circulating monocytes and their IL-6 secretion, greatly improving liver histology, systemic
homeostasis, and survival.
Conclusions: Our study reveals the critical role of monocyte-derived IL-6 in initiating and accelerating acute liver
failure and hUC-MSC treatment can disrupt the development of the inflammatory cascade by inhibiting monocyte
activation. Early hUC-MSC treatment disrupts the development of the inflammatory cascade, indicating a potential
clinical solution for acute liver failure.
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Background
Acute liver failure (ALF), caused by sudden and severe
hepatic injury, is a complicated clinical syndrome
composed of metabolic and immunological dysfunction,
hepatic encephalopathy, coagulopathy, sepsis, and
multi-organ failure. It causes over 60% mortality in west-
ern countries if liver transplantation is not provided.
However, the shortage of donor livers and life-long
immunosuppression have restricted the use of this inter-
vention. The alternative strategies for liver transplant-
ation, such as hepatocyte transplantation, bio-artificial
liver support systems, and tissue-engineering livers, have
been shown as a potential treatment option for ALF
[1, 2]. Nonetheless, the efficacy and safety of these treat-
ment options need to undergo many preclinical studies
before applying in clinical stage. Thus, it is an urgent re-
quirement to develop some new therapeutic methods for
this fatal syndrome.
The pathophysiological process underlying ALF is still
far from clear [2–4]. Given massive parenchymal necro-
sis and hepatic decompensation are the principle cause
of ALF, however, immune system disarrangement, par-
ticularly the excessive activation of the innate immune
system and the systemic release of inflammatory factors,
which is described as a “cytokine storm” [5, 6], has been
regarded as the core event in the process. The resident
hepatic macrophages, known as Kupffer cells, play es-
sential role in the production of various factors that
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initiate and exacerbate the uncontrolled hypercytokine-
mia [7, 8].
We previously established a non-human primate
(Macaca mulatta) model of ALF, in which we induced
ALF with a single intraperitoneal injection of low-dose
α-amatoxin and lipopolysaccharide (LPS) [9, 10]. Follow-
ing the injection of toxins, the monkeys displayed
changes in clinical features, hepatic indexes, histopath-
ology, imaging, and life span that are typical features of
the progress observed in the clinical ALF [9]. Moreover,
monkey is a species with metabolic and physiological
properties similar to those of humans, indicating that
our animal model is appropriate for exploring the patho-
physiology of ALF and for evaluating potential thera-
peutic strategies. Based on this model, we have recently
reported that among the dozens of increased inflamma-
tory factors, IL-6 (interleukin 6) is the most immediately
and dramatically increased cytokine before the appear-
ance of typical changes in serum indices and liver hist-
ology, which acts as a critical trigger that flames the
cytokine storm. Most interestingly, we observed that cir-
culating monocytes (c-Mos), rather than Kupffer cells,
serve as the principal producer of IL-6 before their hep-
atic aggregation and mature differentiation [9]. There-
fore, c-Mos might act as a potential therapeutic target
for this lethal syndrome, and our findings also encourage
early therapies that against the activation of c-Mos prior
to the full development of a cytokine storm.
Mesenchymal stem cells are a type of somatic stem
cells derived from mesodermal tissues, including bone
marrow, fat, cord blood, umbilical cord, placenta, etc.
MSC-based therapies have been widely used for many
diseases [11–13]. Moreover, numerous registered clinical
trials centered on MSC-based treatments are currently
underway worldwide. The therapeutic effects of MSCs
have been extensively evaluated for acute liver injury by
using animal models and in several clinical pilot studies
[10, 14–16]. Interestingly, the results from these studies
have demonstrated that MSCs can protect liver injury
and promote liver repair, differentiate into hepatocytes,
and suppress inflammatory reactions [12, 17, 18]. Thus,
MSCs may represent a potential therapeutic option for
treating ALF. However, it is necessary to accumulate the
efficacy and safety of MSC-based therapies for ALF pre-
clinically before testing in clinical stage.
It has been reported that Wharton’s jelly is one of the
main sources of extracting human MSCs [19]. In recent
years, considerable interest has been given to explore
the therapeutic effects of stem cells due to the exciting
properties. Approximately, one cord provides 100 mil-
lion primary human umbilical cord MSCs (hUC-MSCs),
with extensive in vitro proliferation capacity and after
5-passage culture, they can grow up to 1–10 billion cells
[20]. Previous studies showed that hUC-MSCs can
differentiate into adipocytes, osteocytes, chondrocytes,
neurons, and oligodendrocytes. Compared with MSCs
derived from other mesodermal tissues, hUC-MSCs pos-
sess a higher degree of stemness and provoke lower
levels of immunogenicity [21, 22]. In addition,
hUC-MSCs can secrete a large number of cytokines and
have no tumorigenic effects [19, 20]. These characteris-
tics, along with the ease by which hUC-MSCs are iso-
lated from a tissue with unlimited availability, have
generated much enthusiasm regarding their potential ap-
plications in cell-based therapies. This expectation is be-
ing supported by both preclinical and clinical data [23].
Here, using a toxin-induced monkey model of ALF, we
explored the efficacy and safety of hUC-MSC-based
therapy for ALF. Our work demonstrates that peripheral
infusions of hUC-MSCs profoundly suppressed the acti-
vation of c-Mos and their IL-6 secretion, which resulted
in the prevention of the development of lethal ALF in
monkeys. These results, in combination with those dem-
onstrating the efficacy and safety approach, indicate that
hUC-MSC-based therapies are promising evidence
which need further investigations and validation before
being applied in clinical practice.
Materials and methods
Monkeys
The animal protocols used in this study were approved
by the Institutional Animal Care and Use Committee of
the Traditional Chinese Medicine National Center
(Chengdu, China) (Protocol: IACUC-2012001C). Adult
healthy experimental rhesus monkeys were provided by
Chengdu Ping’an Experimental Animal Reproduction
Center (license no.: SCXK (CHUAN) 2014-013,
Chengdu, China). For a detailed information of the mon-
keys and their treatments, refer to Supplemental mate-
rials and methods Additional file 1: Table S1. To
establish a toxin-induced ALF monkey model, the
α-amatoxin (25 μg/kg bodyweight, Alexis Biochemicals,
Lausen, Switzerland) and LPS (1 μg/kg bodyweight,
Sigma-Aldrich, St. Louis, MO) were diluted in 50ml of
physiological saline and slowly infused into the periton-
eal cavity, which is the same as our published article [9].
hUC-MSCs (human umbilical cord mesenchymal stem
cells)
Human umbilical cords were donated by women who
underwent cesarean sections. Informed consent was ob-
tained from the subjects’ families. hUC-MSCs were col-
lected at the Sichuan Stem Cell Bank, Chengdu, China
and cultured with serum-free medium (Stem cell
05420MesenCultTM-XF Medium, StemRD). For
hUC-MSC quality control, cultured cells at the third
passage (P3) were tested to determine the expression
levels of surface markers by flow cytometry
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(Additional file 1: Figure S1A). To determine the
multi-potential capacity, hUC-MSCs were cultured in
the appropriate conditional medium to induce osteo-
genic and adipogenic differentiation (Additional file 1:
Figure S1B). Moreover, viral factors, pathogenic organ-
isms, and endotoxin levels were monitored (Add-
itional file 1: Table S2). hUC-MSCs were used at P3–5
only when their viability was higher than 95% in all sub-
sequent experiments.
Delivery of hUC-MSCs
For peripheral delivery of hUC-MSCs, 1 × 107 cells were
suspended in 100 ml normal saline, and the infusion rate
of peripheral blood was 35–45 drops/min. It took about
50–60min to complete each 1 × 107 cell infusion.
Statistical analysis
All data was stated as mean (± s.e.m.). Statistical analysis
was performed using GraphPad 5.0 or SPSS 13.0 soft-
ware. Survival was analyzed using a Kaplan–Meier plot
and log-rank analysis. Statistical evaluation of two
groups was performed using Student t test or Mann–
Whitney U test if data were not normally distributed. A
value of P < 0.05 was considered statistically significant.
Other materials and methods are available in the Add-
itional file 1: Supplemental Materials and Methods.
Results
Rhesus monkeys immunologically tolerate human
umbilical cord mesenchymal stem cells
To evaluate whether monkeys tolerate the xenogenic hu-
man cells, we conducted 3 consecutive days of
hUC-MSC infusion (1 × 107 cells/monkey/day) (Add-
itional file 1: Figure S2A and Additional file 1: Table S1).
We did not observe any prominent changes in the im-
mune system in the monkeys after hUC-MSC infusion,
including the numbers of peripheral lymphocytes,
monocytes, and neutrophiles; the ratio of CD4+/CD8+ T
cells, and the proportion of regulatory T cells and ma-
ture dendritic cells (Additional file 1: Figure S2 B-F). In
addition, serum levels of IgA, IgG, and IgM were kept
stable (Additional file 1: Figure S2G). Our data demon-
strated the extremely low immunogenicity of
hUC-MSCs and the xenogeneic cell transplantation is
safe for monkeys.
Peripheral delivery of hUC-MSCs prevents ALF
development in monkeys
Thirteen adult rhesus monkeys were intraperitoneally
administered with toxins. The monkeys were assigned
randomly into two groups based on gender and age: one
group (n = 6) was repeatedly peripherally infused with
1 × 107 hUC-MSCs and another group (n = 7) received
an equal volume of saline at 2 h, 24 h (day 1), and 48 h
(day 2) after challenge with the toxins (Fig. 1a and Add-
itional file 1: Table S1). Liver biopsies and blood collec-
tions were conducted at indicated time points (Fig. 1a).
After a latent period (2 days) following the toxin injec-
tion, the saline-treated monkeys demonstrated progres-
sively deteriorated symptoms and signs including poor
appetite and vomiting, grasping disability, torpidity,
drowsiness, mental indifference, asterixis, and finally,
hepatic coma. The monkeys were euthanized when a
deep coma developed (Fig. 1b). Serum indices, including
liver enzymes, alanine aminotransferase (ALT) and
glutamic-oxaloacetic transaminase (AST), blood ammo-
nia (BA), bilirubin (BIL), and clotting time (prothrombin
time (PT) and activated partial thromboplastin time
(APTT)), were kept stable or slightly increased before
day 2 and then continued to rise and increased by
dozens to hundreds of folds (Fig. 1c). The biopsies
showed that the livers developed apparent steatosis and
mild focal necrosis before day 2 and that severe steato-
sis, patchy and piecemeal necrosis, and sinusoid dilation
and hemorrhage appeared at later times [9].
In contrast, the monkeys that received hUC-MSC in-
fusions consistently maintained good physical and men-
tal conditions and achieved long-term survival (Fig. 1b
and Additional file 1: Table S1). Before day 2, the levels
of serum indicators were not significantly different com-
pared to those of the monkeys that received saline injec-
tion. Then, they increased moderately in the
hUC-MSC-treated animals, peaking between days 4 and
5 before returning to normal levels within approximately
2 weeks (Fig. 1c). Despite the clear presence of steatosis
and a small amount of necrosis in the hepatocytes, the
liver structure was fairly well maintained throughout the
experimental period (Fig. 1d). In follow-up biopsies, the
livers displayed a normal architecture without noticeable
degeneration or fibrosis (Fig. 1e). Moreover, neither
intrahepatic nor extrahepatic tumors were observed in
the recipients during a 3-year follow-up period (data not
shown).
hUC-MSCs neither protect the liver from toxin damage,
promote liver repair, nor regulate adaptive immune
responses
Because amatoxin was cleared within 24 h [24–26] and
because a similar degree of liver damage was observed in
both groups before day 2, the hUC-MSCs did not appear
to protect the hepatocytes from toxin-induced injury. In
addition, the hUC-MSCs were unlikely to have differenti-
ated into hepatocytes within such a short period of time,
let alone that few cells of peripheral origin could localize
in the liver because we failed to detect superparamagnetic
iron oxide (SPIO)-labeled hUC-MSCs using magnetic res-
onance imaging (MRI) or observe fluorescently labeled
cells in liver specimens under fluorescent microscope
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(data not shown). We next investigated whether
hUC-MSCs promoted liver repair. Immunohistochemical
staining of Ki67 in the biopsy tissues showed that the sur-
viving hepatocytes were actively proliferating in all of the
monkeys during the first 4 days regardless of their inter-
vention. Interestingly, the saline-treated monkeys pre-
sented a little higher proliferation indexes during the early
stage (Fig. 1d, e).
Fig. 1 Peripheral delivery of hUC-MSCs ameliorates liver injury and rescues monkeys from lethal ALF. a Schematic representation of the
experimental design. b Survival curves for the monkeys submitted to different treatments (Kaplan–Meier method with log-rank test). c
Biochemical assays of hepatic indexes: alanine aminotransferase (ALT), glutamic-oxaloacetic transaminase (AST), total bilirubin (TBIL), direct
bilirubin (DBIL), prothrombin time (PT), activated partial thromboplastin time (APTT), lactate dehydrogenase (LDH), blood ammonia (BA), uric acid
(UA), and albumin (ALB). Error bars, SEM. Mann–Whitney U test, *P < 0.05, &P < 0.01, and $P < 0.001. d HE staining, Oil red O staining, and Ki67
immunohistochemical staining of liver specimens at indicated days. e Quantitation of Ki67+ positive hepatocytes at indicated time points
following different treatments. The numbers of positive cells in 10 consecutive high-power fields were counted. Student’s t test, each bar
represents the mean ± s.e.m. of positive cells in liver sections from at least three monkeys. f Histology of biopsied liver specimens obtained from
hUC-MSC-treated monkeys after 2 months of follow-up
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Fig. 2 (See legend on next page.)
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We did not observe any prominent changes in the
components of adaptive immunity in the monkeys after
toxin challenge, including the numbers of peripheral
lymphocytes, the ratio of CD4+/CD8+ T cells, the pro-
portion of regulatory T cells and mature dendritic cells
(Fig. 2a, b and Additional file 1: Figure S3), and the
levels of immunoglobulins (Additional file 1: Figure S4).
It appeared that the adaptive immune response plays
minor role in the pathophysiologic process of ALF and
the hUC-MSCs did not modulate antibody- or
cell-mediated immune reactions to protect the liver from
immune injuries.
hUC-MSC infusion suppresses systemic inflammation
Because systemic inflammatory reaction syndrome (SIRS)
acts a critical role in initiating and accelerating ALF [5, 27],
we next investigated whether peripheral infusion of
hUC-MSCs can suppress the cytokine storm. We assessed
the levels of circulating inflammatory factors. In the
saline-treated monkeys, the levels of most factors including
the pro-inflammatory cytokines such as TNF-α, IL-1α,
IL-1RA, and IL-15; the chemokines such as MCP-1,
MIP-1α, and MIP-1β; and the growth factors such as HGF
and b-FGF began to steadily increase on day 2 or later and
reached their peak levels before the animals were sacrificed.
In contrast, in the hUC-MSC-treated monkeys, these fac-
tors consistently remained at baseline levels or displayed a
slight increase. Most noticeably, in the saline-treated mon-
keys, we observed a 30- to 160-fold increase in IL-6 as early
as 1 day after toxin injection. However, in the
hUC-MSC-treated monkeys, IL-6 levels increased only
slightly throughout the experimental period (Fig. 2c). Other
factors, including INF-γ, IL-1β, IL-2, IL-8, IL-10, IL-12,
G-CSF, EGF, Rantes, eotaxin, MIF, I-TAC, MDC, MIG,
IP-10, and EGF, also variably increased, but there was no
significant difference in their levels between the two groups
(Fig. 2c).
hUC-MSC infusion inhibits the activation of circulating
monocytes
As a pro-inflammatory cytokine, IL-6 targets numerous
genes that are known to regulate liver repair following a di-
verse array of injuries [28]. However, excessive production
of IL-6 also acts a critical role in the initiation and
promotion of systemic inflammation. We have revealed
that the activated c-Mos, but not resident Kupffer cells, act
an essential role in IL-6 producing after toxin challenge [9],
and we then assessed whether infusion of hUC-MSCs sup-
presses c-Mos activation. As reported previously [9], in the
saline-treated monkeys, with the increase of IL-6, serum
levels of soluble CD163 (sCD163), which is released
uniquely by activated macrophages [29], were over 100-fold
increased at day 1 (Fig. 3a). In contrast, the levels of
sCD163 were extremely suppressed in the
hUC-MSC-treated monkeys. Unexpectedly, although CD68
staining increased substantially with the progression of
ALF, we did not observe noticeable aggregation of CD68+
cells in the biopsy tissues before day 2 (Fig. 3b, c). The pro-
portion of activated monocytes, characterized by CD14
+CD16+CCR2+ [7, 30], increased substantially in the
saline-treated monkeys, and these cells expressed much
higher levels of IL-6 mRNA (Fig. 3d–f). Furthermore, a
great number of c-Mos, characterized by positive MAC387
immunohistochemistry staining [31], began to recruit in
the liver and differentiate into mature macrophages at day
2 (Fig. 3b, c). On the contrary, the activation and hepatic re-
cruitment of c-Mos were both strongly suppressed in the
hUC-MSC-treated monkeys (Fig. 3b, c). Most noticeably,
the proportion of CD14+CD16+CCR2+ monocytes was re-
duced substantially in these animals (Fig. 3d–f).
Delayed hUC-MSC treatment improves outcomes in
monkeys challenged with toxins
Our data suggested that early infusion of hUC-MSCs
disrupts the inflammatory cascade by inhibiting the
overproduction of monocyte-derived IL-6. However, in
humans, patients seek medications only when their
symptoms become apparent, with their systemic homeo-
stasis already severely impaired. We therefore assessed
whether treatment with hUC-MSCs improves prognoses
in monkeys with fully developed ALF. We began to in-
fuse the monkeys with hUC-MSCs at 24 h after injection
of the toxins (Fig. 4a), since serum IL-6 cytokine levels
reached maximum at this time point and circulating
mononuclear cells also have been highly activated and
expressed IL-6 mRNA according to our previous evi-
dence [9] (Figs. 2c and 3). Although only two of the five
monkeys achieved complete recovery, the other three
(See figure on previous page.)
Fig. 2 hUC-MSCs suppress systemic inflammation. a Count of circulating lymphocytes, neutrophils, and monocytes. b Ratio of CD4+/CD8+ T cells
and proportion of circulating regulatory T cells (Treg; CD4+CD25+FOXP3+) and dendritic cells (DCs; CD1a+CD80+CD86+). c Serum levels of
cytokines, chemokines, and growth factors. EGF, epidermal growth factor; eotaxin, eosinophil chemotactic factor; FGF, fibroblast growth factor; G-
CSF, granulocyte colony-stimulating factor; HGF, hepatocyte growth factor; IL, interleukin; INF-γ, interferon γ; IP-10, interferon-inducible protein-10;
I-TAC, interferon-inducible T cell α chemoattractant; MCP-1, monocyte chemoattractant protein-1; MDC, macrophage-derived chemokine; MIF,
macrophage migration inhibitory factor; MIG, monokine induced by interferon γ; MIP-1α, macrophage inflammatory protein-1α; Rantes, regulated
upon activation normal T cell expressed and secreted; TNF-α, tumor necrosis factor. N = 5–6; error bars, SEM. Mann–Whitney U test, *P < 0.05, &P <
0.01, and $P < 0.001
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Fig. 3 (See legend on next page.)
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Fig. 3 hUC-MSC infusion blocks ALF development by inhibiting the activation of circulating monocytes. a ELISA measurement of serum levels of sCD163 in
the treated monkeys. N=6. b Representative photomicrographs of the results of immunohistochemical staining to identify resident KCs (CD68+) and recruited
hepatic macrophages (MAC387+) in liver tissues. c Quantitation of CD68+ and MAC387+ macrophages. The numbers of CD68+ and MAC387+ cells were
counted in 10 consecutive high-power fields in three monkeys. For each section, 10 randomly chosen portal tracts or areas of central veins were assessed at
high magnification (× 400), and the cumulative number of positive cells in 10 HPF was recorded. d Transcript levels of IL-6 in liver homogenates, circulating
monocytes, and lymphocytes. Each bar represents data obtained from at least three independent quantitative PCR experiments. e, f Flow cytometry analysis of
activated monocytes (CD14+CD16+CCR2+) in subsets of peripheral blood monocyte, N=6. Error bars, SEM. Student’s t test, *P<0.05, &P<0.01, and $P<0.001
Fig. 4 Delayed hUC-MSC treatment improves outcomes in monkeys challenged with toxins. a Schematic representation of the experimental design. b
Survival curves for the monkeys submitted to different treatments (Kaplan–Meier method with log-rank test). c Biochemical assays of hepatic indexes:
alanine aminotransferase (ALT), glutamic-oxaloacetic transaminase (AST), total bilirubin (TBIL), direct bilirubin (DBIL), prothrombin time (PT), activated
partial thromboplastin time (APTT), blood ammonia (BA), and uric acid (UA). Error bars, SEM. Mann–Whitney U test, *P < 0.05. d Serum levels of
cytokines, chemokines, and growth factors. IL, interleukin; TNF-α, tumor necrosis factor; MCP-1, monocyte chemoattractant protein-1; INF-γ, interferon γ;
MIP-1α, macrophage inflammatory protein-1α; MIP-1α, macrophage inflammatory protein-1β. N = 5–7; error bars, SEM. Mann–Whitney U test, *P < 0.05
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monkeys died during the 166–204-h period following
toxin challenge (Fig. 4b and Additional file 1: Table S1),
treatment with hUC-MSCs significantly improved their
hepatic indices (Fig. 4c). Notably, in spite that IL-6 ex-
hibited no significant difference between two groups
throughout the experimental period, other factors, such
as MCP-1, MIP-1α, and MIP-1β, were reduced following
hUC-MSC infusion (Fig. 4d).
hUC-MSCs inhibit monocyte activation in vitro
To further confirm that hUC-MSCs suppress the activa-
tion of c-Mos, we isolated quiescent monocytes from
healthy monkeys and stimulated them with LPS for activa-
tion [32]. After 24 h or 48 h of cultivation, the concentra-
tions of the pro-inflammatory factors such as IL-6, TNF-α,
MCP-1, IL-1α, IL-1β, MIP-1β, and IP-10 increased mark-
edly in the culture medium. When monocytes were
co-cultured with hUC-MSCs in a transwell system, the
concentrations of these cytokines were significantly lower
in the medium (Fig. 5). These data suggested that
hUC-MSCs were actually potent to suppress the activation
of macrophages. Most strikingly, in contrast to most of
the inflammatory factors that were inhibited by the
co-culture of hUC-MSC, IL-10, a well-known inhibitory
factor, was significantly increased after 48-h co-culture.
hUC-MSCs are likely to express inhibitory genes to
suppress monocyte activation
The in vivo mechanism by which hUC-MSCs inhibit the
activation of c-Mos and the production of IL-6 remains
unclear because we could not analyze the activities of the
infused hUC-MSCs. Similarly, in the co-culture system,
we could not determine whether the hUC-MSCs secreted
anti-inflammatory cytokines, such as IL-10, or stimulated
the monocytes themselves to produce such factors. To test
the hypothesis that hUC-MSCs adaptively produce inhibi-
tory cytokines in response to a pro-inflammatory micro-
environment, we stimulated cultured hUC-MSCs using
inflammatory monkey serum (i.e., serum isolated on day 1
following toxin challenge) or inactive serum (i.e., serum
isolated from healthy monkeys). After a 30-min stimula-
tion, the cells were collected for microarray gene expres-
sion profiling. The results revealed that a total of 188 genes
were upregulated while 433 genes were downregulated in
hUC-MSCs (Additional file 1: Figure S5; ArrayExpress ac-
cession number: E-MTAB-4750, https://www.ebi.ac.uk/
arrayexpress/experiments/E-MTAB-4750/). We further an-
alyzed the profiles of the upregulated genes to identify the
networks and biological processes involved in the changes.
We found that components of molecular networks
associated with inflammatory responses, defenses, mono-
cyte differentiation, and myeloid cell differentiation were
upregulated (Fig. 6a). Interestingly, the inhibitory genes Fos,
Socs1, Ssc5d, Zbtb46, Tgfb3, Rab7b, and Tgfbr1, which
negatively regulate cytokine signaling and inflammatory cell
differentiation, inhibit inflammatory activity, or have a role
in immunosuppression, were all found to be expressed at
significantly higher levels (Fig. 6b, c).
Discussion
The development of efficient therapeutics for ALF has
been hindered by the unclear pathogenesis [1]. In this
Fig. 5 hUC-MSCs inhibit the activation of monocytes in vitro. hUC-MSCs suppressed the production of pro-inflammatory factors by monocytes in
co-cultures. IL, interleukin; TNF-α, tumor necrosis factor; MCP-1, monocyte chemoattractant protein-1; MIP-1α, macrophage inflammatory protein-
1α; MIP-1α, macrophage inflammatory protein-1β; GM-CSF, granulocyte–macrophage colony-stimulating factor; IP-10, interferon-inducible protein-
10. N = 6; error bars, SEM. Student’s t test, *P < 0.05, &P < 0.01, and $P < 0.001
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study, by using a large non-human primate model of
ALF, we found that c-Mos and their product IL-6 play
critical roles in initiating and accelerating ALF develop-
ment [9]. The early peripheral infusion of hUC-MSCs
profoundly suppressed the activation of c-Mos and has
improved markedly the hepatic histology, systemic
homeostasis, and animal survival.
Literatures suggest disruption of the immune system,
especially that the dysregulation of the innate immune
system plays a critical role in the development of ALF
[5, 8, 33, 34]. Within the innate immune system, Kupffer
cells (KCs) are the first cell groups which will receive the
“alarm” signals following primary hepatocyte injury [8].
The activated KCs will then produce various cytokines
and chemokines to activate or recruit other inflamma-
tory cells resulting in systemic release of cytokines,
growth factor, and chemokines to restore homeostasis.
At the same time, the hypercytokinemia, also described
as “cytokine storm,” will accelerate the rate of tissue
damage and SIRS [5, 7, 34]. The immune paralysis in
consequent of uncontrolled SIRS is closely associated
with recurrent sepsis and multi-organ dysfunction [5].
Upon liver uptake, amanitin will be fully cleared within
24 h but we did not notice apparent hepatocyte necrosis
within 48 h. Therefore, the mild primary liver injury can
result in severe local tissue damage and systemic disar-
rangement, highlighting the crucial role of the secondary
systemic inflammation in promoting ALF.
We have previously demonstrated that the level of
IL-6 was the most immediately and dramatically
increased cytokine after toxin infusion. As a
pro-inflammatory cytokine, IL-6 targets numerous
immediate-early genes which regulate liver repair mech-
anism following multiple hepatic injuries. Nevertheless,
increased expression of IL-6 often leads to uncontrolled
inflammatory reaction and tissue damage [35, 36]. In
Fig. 6 hUC-MSCs produce inhibitory factors in response to inflammatory stimulation. a Gene ontology term analysis of the primary altered genes
that are associated with the regulation of inflammatory processes. N = 3. b Heat map of the upregulated genes identified in the microarray
analysis. N = 3. c Ingenuity pathway analysis of the network of upregulated inhibitory genes (in red) in hUC-MSCs stimulated by
inflammatory serum
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contrast to the previous findings which report that IL-6
is primarily produced by KCs [5, 28, 35], we did not find
significant activation and expansion of KCs within 48 h
following toxin exposure. In contrary, we found that
c-Mos were the major IL-6 producers before they re-
cruited to the liver and differentiate into mature macro-
phages, making c-Mos as a promising target in
developing treatment for ALF.
The clinical application of MSCs to treat ALF is contro-
versial because of the underlying pathophysiology mechan-
ism of ALF, and functions of MSCs have not yet been
elucidated [18, 37]. We have excluded the possibility that
hUC-MSCs promote liver repair, differentiate into hepato-
cytes, or protect the injured liver by modulating the adap-
tive immunity. Many cytokines were suppressed,
particularly the decreased serum chemokines including
MCP-1, MIP-1α, and MIP-1β, which suggested that periph-
erally delivered hUC-MSCs inhibit the activation of mono-
cytes. The mechanism by which hUC-MSCs interact with
c-Mos remains unclear. It has been established that IL-10
promotes the transition of macrophages from the M1 to
M2 phenotypes [17]. Our results did not directly support
the fact that hUC-MSCs produce IL-10 to suppress the ac-
tivation of c-Mos. Nevertheless, in an in vitro experiment,
when stimulated with inflammatory serum, hUC-MSCs
adaptively produce inhibitory factors that suppress the
activation of innate immune cells and inflammatory re-
sponses. In addition, the peripherally infused hUC-MSCs
have more opportunities to interact with c-Mos.
The potential immunogenicity and tumorigenicity of
hUC-MSCs need to be further investigated before trans-
lated into clinical applications [19, 37]. The study found
that rhesus monkeys tolerated the xenogeneic human
cells, confirming their low immunogenicity and suggest-
ing that it may be feasible to use hUC-MSCs in allogenic
recipients. Moreover, during the 3-year follow-up period,
we found no evidence of any tumors in the animals that
received hUC-MSCs. Thus, hUC-MSCs appear to be
safe for a clinical setting.
The main limitations of this study are the low quantity
of cell count relative to the large size of the animal. This
caused difficulty in tracking and determining peripher-
ally infused cells. Due to the high cost of primates, we
were unable to determine an optimal time frame for cell
infusion. Our findings support the implementation of
early cell therapy prior to the full development of a cyto-
kine storm. Nevertheless, even when the optimal thera-
peutic window for this treatment is missed in a clinical
setting, it still remains a valuable option. Finally, we
did not assess the dose–effect relationship. It is rea-
sonable to speculate that infusing more cells would
be more effective, particularly in patients with fully
Fig. 7 The hypothetical pathway through which hUC-MSC infusion disrupts the development of ALF. Toxin injection destroys hepatocytes (HC),
inducing the release of damage-associated molecular patterns (DAMPs), which activate resident Kupffer cells (KC). KCs then release cytokines
including IL-6, fueling the circulating monocytes (c-Mos) to secret more IL-6 and activate more c-Mos, and as a result, cytokine storm occurs.
Meanwhile, the activated c-Mos migrate to the liver and differentiate into mature macrophages (MФ), which further augment the tissue damage.
Infusion of hUC-MSCs suppresses the activation of c-Mos, thereby disrupting the over activation of inflammatory cascade and the deterioration of
systemic disarrangement
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fueled systemic inflammation, which requires further
evaluation.
Conclusions
We used a large, non-human primate model to provide
novel insights of the underlying cellular and molecular
events of ALF pathogenesis. Our work demonstrates that
peripheral infusions of hUC-MSCs profoundly suppressed
the activation of c-Mos, which resulted in the prevention of
the development of lethal ALF in monkeys (Fig. 7). These
results, in combination with those demonstrating the effi-
cacy and safety approach, indicate that hUC-MSC-based
therapies are promising strategy which need further investi-
gations and validation before being applied in clinical
practice.
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